Drug interactions between Xtandi and Zytiga
Interactions between your drugs
abiraterone ↔ enzalutamide
Applies to:Zytiga (abiraterone) and Xtandi (enzalutamide)
Enzalutamide can significantly reduce the blood levels of abiraterone, which may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Applies to: Zytiga (abiraterone)
Taking abiraterone with food increases the amount of medicine that gets absorbed by the body. This may increase the risk of side effects such as high blood pressure, water retention, and a condition called hypokalemia (low blood potassium), which in severe cases can lead to muscle weakness, paralysis, breathing and swallowing difficulties (due to muscle paralysis), and irregular heart rhythm. You should take abiraterone once a day on an empty stomach. No food should be eaten for at least two hours before and one hour after taking abiraterone. Let your doctor know if you experience nausea, vomiting, constipation, abdominal cramping, confusion, dizziness, lightheadedness, fainting, muscle weakness, muscle cramps, numbness or tingling, rapid heart beat, chest pain, and/or swelling in the legs or feet, as these may be symptoms of hypokalemia or excessive effects of abiraterone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
The recommended maximum number of medicines in the 'antineoplastic hormones' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'antineoplastic hormones' category:
- enzalutamide (active ingredient in Xtandi (enzalutamide))
- abiraterone (active ingredient in Zytiga (abiraterone))
Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.
Drug Interaction Classification
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.